Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer.

Androgen receptor (AR) splice variants (SV) have been implicated in the development of metastatic castration resistant prostate cancer and resistance to AR targeting therapies including abiraterone and enzalutamide. Agents targeting AR-SV are urgently needed to test this hypothesis and further improve the outcome of patients suffering from this lethal disease.

Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Jun 21 [Epub ahead of print]

Adam Sharp, Jonathan Welti, Julian Blagg, Johann S de Bono

Prostate Cancer Targeted Therapy Group, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust., Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research., Cancer Research UK Centre for Cancer Therapeutics, Institute of Cancer Research., Prostate Cancer Targeted Therapy Group, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust .

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe